3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
86
Recurrence
18
Neoplasms
6
Neoplasms, Plasma Cell
3
Lymphoma, Non-Hodgkin
3
Sarcoma, Kaposi
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Leukemia, Myeloid, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Chromosome 17 deletion
2
Burkitt Lymphoma
2
Acquired Immunodeficiency Syndrome
2
Waldenstrom Macroglobulinemia
1
Smoldering Multiple Myeloma
1
Proteostasis Deficiencies
1
Plasmacytoma
1
Plasmablastic Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multi-centric Castleman's Disease
1
Malignant Plasma Cell Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myelomonocytic, Chronic
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Epstein-Barr Virus Infections
1
Interventions
pomalidomide
2
Dexamethasone
2
venetoclax
1
pirtobrutinib
1
pembrolizumab
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
daratumumab
1
acalabrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Chromosome 17 deletion
×
pomalidomide
×
1 year
×
Clear all
NCT01745640
2026-02-05
IFM2010-02
University Hospital, Lille
Phase 2
Completed
63 enrolled
NCT04124497
2025-08-08
DPd
Fondazione EMN Italy Onlus
Phase 2
Active not recruiting
45 enrolled